Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High – Time to Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares reached a new 52-week high during trading on Friday . The company traded as high as $80.29 and last traded at $79.6550, with a volume of 113464 shares trading hands. The stock had previously closed at $78.42.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised 2025 and 2026 revenue guidance, prompting fresh valuation attention and supporting higher expectations for revenue growth going forward. This is a primary driver of the intraday uptick. A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
• Positive Sentiment: Analysts have been revising near-term earnings and EPS forecasts upward (including a raised Q1 EPS estimate), which supports investor sentiment and higher price targets. Upward analyst revisions tend to lift momentum in the shares. Research Analysts Offer Predictions for HALO FY2025 Earnings
• Positive Sentiment: Recent quarterly results (Nov. 3) showed an EPS and revenue beat and strong margins/ROE, reinforcing the thesis that ENHANZE-driven royalties and commercial growth can sustain higher profitability. That fundamental strength underpins current multiple expansion. MarketBeat Halozyme summary and earnings recap
• Neutral Sentiment: Longer-term thematic coverage notes medtech companies seeing multi‑decade growth opportunities; if Halozyme is included in that narrative it could support longer-duration investor interest but is more thematic than immediately catalytic. This medical technology leader sees growth into the 2040s
• Neutral Sentiment: Institutional ownership remains very high (~98%) and analyst ratings are mixed (buys, holds, one sell). That concentration can amplify moves but also limits free float liquidity. MarketBeat institutional & analyst snapshot
• Negative Sentiment: CEO Helen Torley has sold multiple blocks of shares recently (10,000 shares on Feb 5 at ~$78.64; prior sales of 20,000 at ~$76.12 and other sales in 2025/2024). Insider selling can create short‑term pressure or raise governance questions for some investors. Insider Selling: Halozyme Therapeutics CEO Sells 10,000 Shares

Analysts Set New Price Targets

A number of brokerages have commented on HALO. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Morgan Stanley decreased their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Finally, Citizens Jmp lifted their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics Price Performance

The stock has a market capitalization of $9.55 billion, a PE ratio of 17.10, a PEG ratio of 0.34 and a beta of 0.97. The company has a 50-day moving average of $69.43 and a 200 day moving average of $69.16. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $68.48, for a total value of $136,960.00. Following the transaction, the director owned 42,952 shares of the company’s stock, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 71,398 shares of company stock worth $5,170,152 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of HALO. Mizuho Markets Americas LLC grew its position in shares of Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after buying an additional 926,526 shares in the last quarter. LSV Asset Management grew its stake in Halozyme Therapeutics by 2.8% during the 4th quarter. LSV Asset Management now owns 1,301,055 shares of the biopharmaceutical company’s stock worth $87,561,000 after buying an additional 35,028 shares during the last quarter. Pzena Investment Management LLC grew its position in shares of Halozyme Therapeutics by 4.2% during the fourth quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 171 shares during the last quarter. Global Retirement Partners LLC grew its position in Halozyme Therapeutics by 44.8% during the 4th quarter. Global Retirement Partners LLC now owns 2,046 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 633 shares during the last quarter. Finally, Twin Capital Management Inc. acquired a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $758,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.